UniQure N.V. said it is pleased with a new interim readout from its Phase I/II US trial of AMT-130, a gene therapy candidate for Huntington’s disease, but the response of its investors on 21 June suggests concern about a dataset that at least one analyst called “mixed.”
UniQure’s Mixed Data In Huntington’s May Slow Firm’s Momentum
UniQure’s Phase I/II interim readout in Huntington’s disease showed improvements on functional and clinical measures, but mixed results on a pair of biomarkers.
